Abstract Purpose: t(12;21)(p13; q22), present in f25% of pediatric precursor B-ALL, is highly sensitivity to L-asparaginase and the prognosis depends on the intensity of the treatment protocol. This study analyzes the relationship between the mRNA expression of the genes and fusion products involved in t(12;21), in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, and longterm clinical outcome in t(12;21)+ acute lymphoblastic leukemia (ALL) patients. Experimental Design: Long-term clinical outcome in 45 t(12;21)+ ALL patients was related to mRNA expression of TEL, AML1, TEL-AML1, and AML1-TEL, determined by real-time quantitative PCR, and the in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Results: A significant f3.5-fold lower TEL expression in t(12;21)+ compared with t(12;21)À ALL samples (P = 0.006) and normal controls (P = 0.004) was found. Expression of AML1 did not differ between t(12;21)+ and t(12;21)À ALL. However, AML1 expression in the leukemic cells was 2-fold higher compared with normal controls (P = 0.02). TheTEL-AML1 fusion product was expressed in all t(12;21)+ cases, whereas the reciprocal fusion product AML1-TEL was expressed in only 76%. High expression levels of TEL-AML1 [hazard ratio (HR), 1.3; 95% confidence interval (95% CI), 1.10-1.57; P = 0.003], AML1-TEL (HR, 4.9; 95% CI, 1.99-12.40; P = 0.001) and AML1 (HR, 1.1; 95% CI, 1.03-1.22; P = 0.006) were associated with a poor long-term clinical outcome within t(12;21)+ ALL. Cellular drug resistance towards prednisolone, vincristine, and L-asparaginase could not explain this predictive value. Multivariate analysis including age and WBC showed that only high AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL. Conclusion: High AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL.
The t(12;21)(p13;q22) occurs in f25% of childhood acute lymphoblastic leukemia (ALL) and is restricted to precursor Bcell leukemia. The t(12;21) involves fusion of the TEL (ETV6) gene at 12p13 with the AML1 (CBFA2/RUNX1) gene at 21q22. The breakpoint most often occurs in intron 5 of TEL and intron 1 of AML1. A frequent translocation variant results in fusion between intron 5 of TEL and intron 2 of AML1. The TEL gene is a member of the ETS family of transcription factors and functions as a transcriptional repressor (1) . AML1 encodes a transcription factor that acts as a transcription activator as well as a transcriptional repressor (2) . Both genes are frequent targets of chromosomal translocations in a variety of myeloid and lymphoid leukemias (3, 4) .
Since the discovery of t (12;21) , several studies addressed the prognostic value of this particular translocation (reviewed by Loh and Lubnitz; ref. 5) . In general, t(12;21)-positive ALL is associated with a favorable prognosis although conflicting results have been reported (5) . In the Dutch Childhood Oncology Group ALL-7 and ALL-8 treatment protocols, no prognostic value was found for t(12;21)-positive ALL (6) . In addition, the t(12;21)-positive ALL group does not seem to be a homogenous group, because F20% of the Dutch t(12;21)-positive ALL patients relapsed. 5 Furthermore, additional genetic changes in TEL and AML1 e.g., deletion of the nontranslocated TEL gene, an additional copy of AML1 , an extra der(21)t (12;21) , or combinations of these genetic abnormalities in t(12;21)-positive ALL are present in >80% of patients. 5 We recently showed that the absence of additional genetic changes in TEL and AML1 as well as the presence of an extra der(21)t (12;21) are associated with an unfavorable prognosis within t(12;21)-positive ALL, which is not independent from prednisolone resistance. 5 In the present study, we analyzed whether the expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL are associated with drug sensitivity and long-term clinical outcome in t(12;21)-positive ALL.
Materials and Methods
Patient samples. Bone marrow and peripheral blood samples from untreated children with common/pre B-ALL at initial diagnosis were collected from the Erasmus MC, Sophia Children's Hospital, the Dutch Childhood Oncology Group and the German Childhood Acute Lymphoblastic Leukemia study group. Bone marrow and/or peripheral blood samples from the Erasmus MC, Sophia Children's Hospital from children who turned out to be nonleukemic were included as controls. Within 24 hours after sampling, mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (density, 1.077 g/mL; Nycomed Pharma, Oslo, Norway). Contaminating nonleukemic cells in the ALL samples were removed by immunomagnetic beads as described earlier (7) . All resulting samples contained z90% leukemic cells, as determined morphologically on May-Grü nwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins. For RNA extraction, a minimum of 5 Â 10 6 leukemic cells were lysed in Trizol reagent (Life Technologies, Gaithersburg, MD) and stored at À80jC. Leukemic cells (25 Â 10 3 ) were used for cytospin preparations and stored at À20jC.
Fluorescence in situ hybridization analysis. The presence of the t(12;21) was determined on cytospin preparations with dual-colored fluorescence in situ hybridization (FISH; ref. 8) using a digoxigeninlabeled cosmid from intron 1 to exon 2 of TEL (50F4), together with a biotinylated cosmid for the first five exons of AML1 (CO664). FISH probes were kind gifts of Dr. N. Sacchi, University of Milan, Italy (ref. 9; CO664) and Prof. Dr. P. Marynen, Human Genetics, University of Leuven, Belgium (ref. 10; 50F4). Probe 50F4 was visualized with Texas Red and probe CO664 with FITC. In t(12;21)-positive patients a yellow fusion spot will be visible denoting the der(21)t(12;21), one green signal for the normal AML1 on chromosome 21, and one red signal for the normal TEL on chromosome 12 if not deleted. In all instances, two independent observers examined 100 to 300 interphase nuclei each.
In vitro L-asparaginase, prednisolone, and vincristine cytotoxicity assay. In vitro L-asparaginase, prednisolone, and vincristine cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as described previously (11) . Briefly, 100-AL aliquots of cell suspension (1.6 Â 10 5 cells) were cultured in round-bottomed 96-well microtiter plates in the presence of six concentrations of L-asparaginase (Paronal, Christiaens B.V., Breda, the Netherlands) ranging from 0.0032 to 10 IU/mL, prednisolone (Bufa B.V., Uitgeest, the Netherlands) ranging from 0.08 to 250 Ag/mL, and vincristine sulfate (TEVA Pharma BV, Mijdrecht, the Netherlands) ranging from 0.049 to 50 Ag/mL in duplicate. Control cells were cultured without L-asparaginase, prednisolone, or vincristine. After incubating the plates for 4 days at 37jC in humidified air containing 5% CO 2 , 10 AL of 3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazoliumbromide (5 mg/mL; Sigma Aldrich, Zwijndrecht, the Netherlands) were added. During a 6-hour incubation, the yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium salt is reduced to purple-blue formazan crystals by viable cells. Samples with z70% leukemic cells in the control wells and an absorbance higher than 0.050 arbitrary units (adjusted for blank values) were used to calculate the concentration of drug lethal to 50% of the cells (LC 50 ).
Real-time quantitative PCR. The t(12;21)-positive ALL patients with sufficient material available were selected to perform real-time quantitative PCR, but patients were selected without preexisting knowledge about the clinical outcome of these patients. Total cellular RNA was extracted from a minimum of 5 Â 10 6 (z90% leukemic) cells using Trizol reagent (Life Technologies) according to the manufacturer's protocol, with minor modifications that improved the quality of RNA. cDNA was synthesized using random hexamers and oligo dT as published previously (12) . The mRNA expression levels of TEL, AML1, TEL-AML1, and AML1-TEL and as a reference the endogenous housekeeping gene encoding for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were quantified using real-time PCR analysis (Taqman chemistry) on an ABI Prism 7700 sequence detection system (PE Applied Biosystems, Foster City, CA). Amplification of specific PCR products was detected using dual-fluorescent nonextendable probes labeled with 6-carboxyfluorescein at the 5V -end and 6-carboxytetramethylrhodamine at the 3V -end. The primers and probe combinations were designed using the OLIGO 6.22 software (Molecular Biology Insights, Cascade, CO) and purchased from Eurogentec (Seraing, Belgium). The forward and reverse primer and probe combinations were, respectively, 5V-ACCCTCTGATCCTGAACC-3V, 5V-CCGTTGGGATCCACTATC-3V and 5V-TCATCGGGAAGACCTGGCTT-3V for TEL ; 5V-GACAGCCC-
, 5V-CATCCGTGGACGTCTCT-3V and 5V-TCATCGGGAAGACCTGGC-TT-3V for TEL-AML1; 5V-GAGTCCCAGAGGTATCCAG-3V, 5V-AATCCCA-AAGCAGTCTACA-3Vand 5V-TGACCTGTCTTGGTTTTCGC-3Vfor AML1-TEL; 5V-GTCGGAGTCAACGGATT-3V, 5V-AAGCTTCCCGTTCTCAG-3V and 5V-TCAACTACATGGTTTACATGTTCCAA-3V for GAPDH. All primers had a melting temperature (T m ; nearest neighbor method) of 65jC to 66.5jC at salt concentration of 303 mmol/L of Na + equivalent and 300 nmol/L of primer concentration. Both internal probes had a T m of 75 F 1jC. All PCRs done at comparable efficiencies of z95%. The real-time quantitative PCR was done under the same conditions as described before (12) . The comparative cycle time (C t ) value is the target PCR C t value normalized by subtracting the GAPDH C t value from the target PCR C t value. From this DC t value, the relative expression level to GAPDH in arbitrary units (AU) for each target PCR can be calculated using the following equation: relative mRNA expression = 2 ÀDC t Â 100.
Statistics. Disease-free survival (pDFS) was calculated from the date of diagnosis to the date of nonresponse, relapse, or last contact. The failure to achieve complete remission at day 56 (nonresponse) was considered an event at day 56. pDFS curves were calculated according the Kaplan-Meier method and compared by the Cox proportional hazard regression model. Multivariate analysis was done with the Cox proportional hazard regression model. Statistical tests were done at a two-tailed significance level of 0.05. Differences in the distribution of variables between groups of patients were analyzed using the MannWhitney U test. Bivariate correlations were calculated using the Spearman's rank correlation test.
Results
The mRNA expression levels of TEL, AML1, TEL-AML1, and AML1-TEL were measured in 45 t(12;21)-positive pediatric ALL samples that were validated by FISH analysis. A control group of 26 t(12;21)-negative ALL samples was selected by matching for the following criteria: age 1 to 10 years, immunophenotype, no hyperdiploidy (>50 chromosomes), and no MLL rearrangements and no t(9;22). Furthermore, a nonleukemic control group containing both bone marrow and peripheral blood samples (n = 14) was selected to compare TEL and AML1 expression in normal and leukemic cells.
TEL-AML1, AML1-TEL, AML1, and TEL mRNA Expression and Drug Resistance. Expression of the fusion product TEL-AML1 was present in all 45 t(12;21)-positive ALL patients tested, whereas the AML1-TEL expression was present in only 76% of these cases. We compared the data on the presence of an extra der(21)t(12;21) to the mRNA expression of TEL-AML1 and AML1-TEL (Fig. 1) . The expression of these fusion genes did not differ between patients with and without an extra der(21)t(12;21) (P = 0.5 and P = 0.3, respectively). No significant correlation was found between the expression of these fusion genes and sensitivity to L-asparaginase, prednisolone, or vincristine (À0.233 > R s < 0.102, P > 0.05).
Expression of AML1 did not significantly differ between 45 t(12;21)-positive and 26 t(12;21)-negative ALL (P = 0.9; Interestingly, patients with a deletion of the nontranslocated TEL allele still shown detectable TEL mRNA expression levels (Fig. 3B) . Further examination revealed that this mRNA is derived from contaminating normal cells in the t(12;21)-positive ALL samples (Fig. 3C) . Despite the fact that our samples were purified towards >90% leukemic cells, the presence of <10% contaminating normal cells contributed to detectable TEL mRNA levels. Furthermore, FISH analysis showed that a deletion of the second TEL allele is not present in 100% of the leukemic cells. expression below 75th percentile of total group; 3-year pDFS 93 F 5%; P = 0.004; Fig. 4A ). In addition, high expression of AML1-TEL (3-year pDFS 51 F 25%; P = 0.008; Fig. 4B ) and AML1 (3-year pDFS 25 F 22%; P = 0.004; Fig. 4C ) were related to a poor outcome. Cox regression analysis using the mRNA expression levels of TEL-AML1, AML1-TEL, and AML1 as continuous variables also indicated that an increase in expression is associated with an increase in relapse risk in t(12;21)-positive ALL, whereas an increase in AML1 expression in t(12;21)-negative ALL does not relate with an increased relapse risk (Table 1 ). In addition, a multivariate analysis including also the known prognostic factors age and WBC at diagnosis was done (Table 2) . In this analysis, only increased expression of AML1-TEL was associated with a poor prognosis in t(12;21)-positive ALL (hazard ratio, 7.02; 95% confidence interval, 2.01-24.52; P = 0.002). High expression of TEL-AML1 mRNA was correlated with high expression of AML1 (R s = 0.524; P < 0.001). This can explain the fact that both TEL-AML1 and AML1 are no independent prognostic factors in the multivariate analysis. The expression of AML1-TEL was not related to either TEL-AML1 or AML1 expression (R s = 0.126, P = 0.4 and R s = 0.097, P = 0.5, respectively).
Discussion
In the present study, we examined the relation among TEL, AML1, TEL-AML1, and AML1-TEL mRNA expression, the additional genetic changes in TEL and AML1 genes, the in vitro sensitivity to L-asparaginase, prednisolone, and vincristine, and clinical outcome in children with t(12;21)-positive ALL at initial diagnosis.
A significantly lower expression of TEL was found in t(12;21)-positive ALL patients compared with t(12;21)-negative ALL patients and normal controls. This can be explained by the fact that the nontranslocated TEL allele is frequently (F70%) deleted in t(12;21)-positive ALL 5 (13 -15) . Thus far, only one earlier study analyzed the mRNA expression of wild-type TEL in childhood acute leukemia (16) solid line, low expression (P < 75). Differences in pDFS were analyzed by the Cox proportional hazard regression model (P cox ). A, high expression is associated with an unfavorable prognosis (3-year pDFS 30 F 25%) compared with low expression (3-year pDFS 93 F 5%; P cox = 0.004; P cox continous variable = 0.003; seeTable 2). B, high expression is associated with an unfavorable prognosis (3-year pDFS 51 F25%) compared with low expression (3-year pDFS 93% F 6%; P cox = 0.008; P cox continous variable = 0.001; seeTable 2). C, high expression is associated with an unfavorable prognosis (3-year pDFS 25 F 22%) compared with low expression (3-year pDFS 93 F 5%; P cox = 0.004; P cox continous variable = 0.006; see Table 2 ).
Imaging, Diagnosis, Prognosis
Cancer Research. No difference in AML1 expression was found between t(12;21)-positive ALL patients (with or without an additional copy of AML1) and t(12;21)-negative ALL patients, although only in t(12;21)-positive ALL patients high AML1 expression is related to a poor outcome. Our data show that AML1 expression is significantly elevated in both ALL subgroups compared with the normal control group. This might be due to the fact that expression of AML1 is required for proliferation since AML1 regulates G 1 to S cell cycle transition (17, 18) . Although the AML1 expression in t(12;21)-positive and t(12;21)-negative ALL is comparable, differences in cell cycle are present in these two groups of ALL. The percentage of cells in S phase is lower in t(12;21)-positive ALL compared with t(12;21)-negative ALL (19) . This might be explained by the fact that in t(12;21)-positive patients TEL-AML1 competes with wild-type AML1 to bind the DNA and acts as a transcriptional repressor of AML1 target genes (20) .
Conflicting data on the prognostic relevance of t(12;21)-positive ALL have been reported ranging from 60% to 100% survival (reviewed by Loh et al.; refs. 5, [21] [22] [23] [24] . Initially, studies reported favorable outcome of t(12;21)-positive ALL patients compared with t(12;21)-negative ALL patients. Later on, several studies could not confirm this prognostic relevance, among which Dutch Childhood Oncology Group -treated t(12;21)-positive ALL 5 (6) . The intensity of treatment given to t(12;21)-positive ALL patients seems to contribute to a favorable outcome (25 -27) . Our data show that a high expression of TEL-AML1, AML1-TEL, and AML1 are related to a poor prognosis in pediatric t(12;21)-positive ALL. However, only the expression of AML1-TEL is an independent prognostic factor in t(12;21)-positive pediatric ALL. Current research focuses on determining the function of the TEL-AML1 fusion protein in leukemogenesis, because the TEL-AML1 fusion product is expressed in all t(12;21)-positive ALL cases, whereas the reciprocal fusion product AML1-TEL is not. In mouse models, TEL-AML1 alone is insufficient for leukemogenesis but may result in leukemia when additional mutations are present (28, 29) . The presence of AML1-TEL expression did not make a difference in inducing hematologic disease in transgenic mice (28) . The TEL-AML1 fusion product was detected in neonatal blood spots and cord blood samples at a hundred times higher frequency than expected from the corresponding leukemia incidence (30, 31) . This finding together with the mouse model studies suggests that secondary additional genetic changes are required for leukemogenesis. As the second TEL allele is most frequently deleted in t(12;21)-positive ALL, it is speculated that wild-type TEL acts as a tumor suppressor gene and its deletion in t(12;21)-positive ALL is the second hit required for leukemogenesis. However, 30% of the t(12;21)-positive ALL patients do not show a deletion of TEL indicating that another genetic abnormality is necessary for leukemogenesis. In a previous study, we showed the absence of additional genetic changes in TEL and AML1 genes as well as an extra der(21)t(12;21) are associated with an unfavorable prognosis in pediatric t(12;21)-positive ALL. 5 As shown in the present study, expression levels of TEL-AML1 and AML1 were not increased in patients with an extra der(21)t(12;21) or an additional copy of AML1 respectively. However, this might be due to the fact that the discrimination level of the RTQ-PCR is minimal 2-fold.
As shown in the present study, AML1-TEL expression levels are associated with outcome. Resistance to prednisolone, vincristine, or L-asparaginase cannot explain this predictive value. Therefore, AML1-TEL may be involved in cell regrowth rather than in toxic response pathways. The AML1-TEL fusion product contains exon 1 or exons 1 and 2 of AML1, in which no functional domain is present and the last three exons of TEL, which contains the ETS domain. In the TEL gene, a repression domain was identified which encompasses the ETS (1) . It is hypothesized that ETS proteins with transcriptional repression activity (like TEL) are primarily involved in ensuring the balance between cellular proliferation and differentiation in different cell types and developmental stages, in response to extracellular signals (32) . The isolated ETS domain of TEL binds conventional ETS binding sites in vitro and regulates ETS binding site -driven transcription (33 -35) . It can be hypothesized that AML1-TEL acts comparable to an isolated ETS domain and competes for binding with the endogenous TEL or acts like TEL in the absence of wild-type TEL. Therefore, it seems unlikely that AML1-TEL will not have a function in t(12;21)-positive ALL. This is the first study showing that AML1-TEL expression is associated with prognosis in t(12;21)-positive ALL. Further characterization and validation of AML1-TEL expression is required to determine the therapeutic implications of the AML1-TEL expression levels in t(12;21)-positive ALL.
